



For Immediate Release
16.September.2009

For more information, contact
Veronica Palacios at +1.301.214.7624

Cardiocore Scientist to Present at DIA Cardiovascular Safety for Diabetes Conference

Dr. Nelson Schiller Will Define Value of ECHO Testing in Anti-diabetic Clinical Trials

Washington, DC— Cardiocore, a premier centralized cardiac testing lab, announced today that its Senior Scientist, Nelson Schiller, MD, FACC, will present at the *Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications: Current State of the Art and Opportunities to Advance the Science* conference, along with FDA and other industry experts. The meeting will be held in Washington, DC on September 23-24, 2009.

Dr Schiller's talk, *The Value of Echocardiography for Diabetic Studies*, will focus on the critical relationship between diabetes and heart failure. He will identify the importance of echocardiography (ECHO) for early detection of diabetic cardiomyopathy, and will present data related to assessment of systolic and diastolic function.

Dr. Schiller is a well known expert in the application and interpretation of echocardiography. He founded the University of California San Francisco (UCSF) Echocardiography Laboratory and its Adult Congenital Heart Disease Clinic. He has played integral roles in the development of many diagnostic and treatment techniques including transesophageal echocardiography, Doppler pulmonary pressure determination, myocardial contrast perfusion and echocardiography phase imaging for ventricular coordination.

As will be discussed at the conference, the cardiac risks associated with diabetes are well documented. According to both the American Heart Association and the American College of Cardiology, cardiovascular complications are the most common causes of morbidity and mortality in diabetic patients. The Framingham Heart Study has shown that the incidence of congestive cardiac failure in diabetic patients occurs irrespective of coronary artery disease or hypertension.

Details about this important scientific meeting may be accessed through Cardiocore's web site at <http://www.cardiocore.com/news/events/>.

About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 17 years. Services include centralized electrocardiography (ECG), Holter monitoring, echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development and statistical analysis. The company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England.
www.cardiocore.com